Poster presented by Biofortis at the Annual AACR Congress (USA, New Orleans, 16-20 April 2016)

Discover and Share the Newsletter IMODI #1 – July 2016
13/07/2016
ESBB Vienna 2016
Join ModulBio at the ESBB Vienna 2016, booth 45
13/09/2016

Poster presented by Biofortis at the Annual AACR Congress (USA, New Orleans, 16-20 April 2016)

IMODI Initiative:
a Novel Holistic and Integrative Approach with Patient-Derived Tumor Models

Introduction

The national IMODI (Innovative MODels Initiative) consortium includes 25 partners (pharma, SMEs, academic research labs and clinical centers) with the aim of developing more predictive tools to improve the selection of new effective treatments to combat 9 cancer pathologies. These developments include:
  • Collection of in-vivo PDX models (procedures were approved by Animal Care Committees, according to ethical guidelines for animal care and handling)
  • Collection of in-vitro derived cell lines,
  • 2D & 3D ex-vivo assays,
  • In-vivo humanized models (immune system, liver and tumour stroma),
  • Characterization of tumour histology, gene mutations, gene expression, pharmacological responses and gut microbiota,
  • Biobanks of tumours, blood, serum and stools (patient specimens were obtained from 7 clinical centers with written informed patient consent for providing surgical tumor samples and for HIV1&2, HTLV1&2, HBV and HCV serological status testing),
  • Central database,
  • Datamining,
Results on NSCLC lung cancer xenograft developments, molecular and pharmacological characterizations and data analysis are presented as an example of the IMODI holistic and integrative approach.
 
 
Share this